Join PER® September 15th for the New York Advanced Practice Collaborative Meeting! Directed toward NP/PAs, this meeting blends presentations on cutting-edge information with panel discussions to enhance learning.

Metastatic Colorectal Cancer Treatment

Tuesday, March 11, 2014
Researchers from the Dana Farber Cancer Institute in Boston retrospectively examined patterns of care and predictors of treatment approaches for 4,877 patients with metastatic colorectal cancer. Data entered into the Intellidose chemotherapy order entry system at academic, private, and community-based oncology practices across the United States between January 2004 and March 2011 were analyzed. The order entry system captured disease stage, patient demographics, provider characteristics, and chemotherapy regimen selection. Multivariable analyses were used to identify independent predictors of treatment decisions. Throughout the study period, a fluoropyrimidine/oxaliplatin combination was the most commonly used first-line chemotherapy regimen, representing 71% of first-line therapy by 2007. First-line bevacizumab use averaged 51% and peaked at 55% in 2006. Of those who received first-line bevacizumab, 34% continued to receive bevacizumab as second-line treatment.

Only 26% of patients received an anti-EGFR monoclonal antibody (cetuximab = 22%; panitumumab = 6%) at some point in their treatment course. Patients treated at academic centers, with longer duration of first-line therapy, and at sites in the western United States were statistically more likely to receive an anti-EGFR antibody. Anti-EGFR antibody use fell by 18% after the Food and Drug Administration limited its use to patients with KRAS wild-type tumors in June 2009. The researchers noted that even in academic centers, only 50% of patients were tested for KRAS mutations, and concluded that the study presents a portrait of real-world practice.
Reference Abrams TA, Meyer G, Schrag D, et al. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst (2014) 106 (2): djt371 doi: 10.1093/jnci/djt371

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.